GlassScriptPhysician profile
James Paul Wagner
NPI 1851469480
$594.66
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $91.53 · 2021: $221.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $187.18 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $131.38 | 2019-2021 | |
| Amgen INC. | $50.67 | 2019 | |
| Redhill Biopharma INC. | $42.28 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $39.89 | 2019 | |
| Pfizer INC. | $33.95 | 2020-2021 | |
| Abbott Laboratories | $22.14 | 2021 | |
| Mylan Specialty L.P. | $21.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.91 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.75 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.73 | 2021 | |
| Vifor Pharma, INC. | $11.60 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.